| The Development of Novel Therapies for Rheumatoid Arthritis. | |
| | |
MedLine Citation:
|
PMID: 19578469 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
BACKGROUND: Rheumatoid arthritis (RA) is a chronic, systemic, inflammatory disease that affects approximately 0.5 to 1 percent of the adults worldwide and commonly results in joint destruction and significant impairment in the quality of life. RA is considered as an autoimmune disease with unknown etiology. Many pathogenic pathways of RA have been revealed recently, which led to development of various novel therapies. OBJECTIVE: The current treatments of RA include 4 categories: non-steroidal anti-inflammatory drugs (NSAIDs), glucocorticoids, non-biologic disease-modifying anti-rheumatic drugs (DMARDs) and biologic DMARDs. In this review, we will discuss some of the most recent development in antirheumatic therapies. METHODS: Using SciFinder Scholar and PubMed as main searching tools, we evaluated various newly developed therapies for RA. Under each drug category, emphases are placed on the mode of action, limitation of the drugs and new drug candidates from the patents search. Those well-established therapies will only be reviewed briefly. CONCLUSION: During the past 20 years, most of the development of new therapies is in DMARDs, especially biological DMARDs. With the discovery of new pathways and the application of drug delivery strategies, more growth is anticipated in this research field. |
| | |
Authors:
|
Ling-Dong Quan; Geoffrey M Thiele; Jun Tian; Dong Wang |
Related Documents
:
|
3123369 - Isoelectric focusing characterization of igm-vkiiib immunoglobulin light chains and the... 17542999 - Has the use of disease-modifying anti-rheumatic drugs changed as a consequence of contr... 6395229 - Clinical trials on the efficacy and toxicity of slow acting antirheumatic drugs. 7914739 - Disease-modifying antirheumatic drugs, including methotrexate, sulfasalazine, gold, ant... 18360649 - Abatacept in the treatment of rheumatoid arthritis. 18390589 - Rheumatoid arthritis patients who smoke have a higher need for dmards and feel worse, b... 12150849 - Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a prop... 18783609 - Fatal hemolytic anemia associated with metformin: a case report. 11741629 - Prescription-event monitoring and reporting of adverse drug reactions. |
Publication Detail:
|
Type: JOURNAL ARTICLE |
Journal Detail:
|
Title: Expert opinion on therapeutic patents Volume: 18 ISSN: 1744-7674 ISO Abbreviation: Expert Opin Ther Pat Publication Date: 2008 Jul |
Date Detail:
|
Created Date: 2009-7-21 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9516419 Medline TA: Expert Opin Ther Pat Country: - |
Other Details:
|
Languages: ENG Pagination: 723-738 Citation Subset: - |
Affiliation:
|
Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE 68198, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
| Grant Support | |
ID/Acronym/Agency:
|
R01 AR053325-02//NIAMS NIH HHS |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Gamma hydroxybutyric acid (GHB) for the treatment of alcohol dependence: a review.
Next Document: Let's Talk About Race, Baby! When Whites' and Blacks' Interracial Contact Experiences Diverge.